[Revaluation of current antimicrobials. Series 17: Arbekacin sulfate].
Hayashi
I
I
Inoue
M
M
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy*; D003982:Dibekacin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin